Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Biomarkers is Scopus-indexed (Q2, CiteScore 4.3), WoS SCIE. Published by SAGE Publications Ltd.
Checked against the index lists dated .
ISSN 1574-0153Verify ISSN ↗1875-8592Verify ISSN ↗
Publisher: SAGE Publications Ltd
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 201 / 428 | 53rd | Q2 |
| Genetics | 182 / 357 | 49th | Q3 |
| Cancer Research | 150 / 233 | 35th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2005–present, best quartile Q2, CiteScore 4.3.
Cancer Biomarkers is Q2 in Oncology (rank 201 of 428), Q3 in Genetics (rank 182 of 357) and Q3 in Cancer Research (rank 150 of 233), by CiteScore 2025.
Cancer Biomarkers is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.3, which places it in quartile Q2 at the 53rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.572, quartile Q2, with an H-index of 60.
Cancer Biomarkers is published by SAGE Publications Ltd. Its print ISSN is 1574-0153 and its online ISSN is 1875-8592.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Biomarkers has an h-index of 68 and a 2-year mean of 2.67 citations per paper (OpenAlex). Its Scopus CiteScore is 4.3, quartile Q2. On 2-year citations it ranks #136 of 424 Scopus journals in Oncology.
Cancer Biomarkers published 62 papers in 2025; its busiest recent year was 2017 with 241. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2024–2026), authors are most often from China (58.6%), United States (14%) and Türkiye (6.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 58 retracted papers are recorded (27.1 per 1,000 papers). The Problematic Paper Screener flags 7 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.